908 Devices (MASS) Competitors

908 Devices (NASDAQ:MASS) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation, institutional ownership and community ranking.

Do analysts rate MASS or TRNS?

908 Devices currently has a consensus target price of $5.33, suggesting a potential upside of 12.52%. Transcat has a consensus target price of $114.00, suggesting a potential upside of 24.84%. Given Transcat's higher possible upside, analysts clearly believe Transcat is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Transcat	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Which has more volatility & risk, MASS or TRNS?

908 Devices has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Transcat has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500.

Does the MarketBeat Community favor MASS or TRNS?

Transcat received 193 more outperform votes than 908 Devices when rated by MarketBeat users. Likewise, 66.04% of users gave Transcat an outperform vote while only 47.50% of users gave 908 Devices an outperform vote.

Company	Underperform	Outperform
908 Devices	Outperform Votes 19 47.50%	Underperform Votes 21 52.50%
Transcat	Outperform Votes 212 66.04%	Underperform Votes 109 33.96%

Which has stronger valuation & earnings, MASS or TRNS?

Transcat has higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$63.99M	2.66	-$36.40M	-$0.54	-8.78
Transcat	$272.20M	3.12	$13.65M	$1.85	49.36

Is MASS or TRNS more profitable?

Transcat has a net margin of 6.22% compared to 908 Devices' net margin of -109.11%. Transcat's return on equity of 7.23% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-109.11%	-24.60%	-19.23%
Transcat	6.22%	7.23%	5.67%

Do institutionals & insiders have more ownership in MASS or TRNS?

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 27.7% of 908 Devices shares are owned by insiders. Comparatively, 2.3% of Transcat shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media refer more to MASS or TRNS?

In the previous week, 908 Devices had 4 more articles in the media than Transcat. MarketBeat recorded 15 mentions for 908 Devices and 11 mentions for Transcat. 908 Devices' average media sentiment score of 0.88 beat Transcat's score of 0.21 indicating that 908 Devices is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Transcat beats 908 Devices on 13 of the 17 factors compared between the two stocks.